MBX Biosciences Catapults 125%, Hitting A Nine-Month High, On Thyroid Drug PromiseInvestors Business Daily • 09/22/25
MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label ExtensionGlobeNewsWire • 09/22/25
MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22GlobeNewsWire • 09/19/25
MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of ObesityGlobeNewsWire • 09/04/25
MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 08/07/25
MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical DevelopmentGlobeNewsWire • 06/23/25
MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of ObesityGlobeNewsWire • 06/16/25
MBX Biosciences to Present at the American Diabetes Association 85th Scientific SessionsGlobeNewsWire • 06/10/25
MBX Biosciences: Consider Peptide Developer With GLP Drugs As A Speculative BuySeeking Alpha • 05/31/25
MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 05/12/25
MBX Biosciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 03/26/25
MBX Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/17/25
MBX Biosciences Completes Enrollment in Phase 2 Avail™ Trial of MBX 2109 (Canvuparatide) for HypoparathyroidismGlobeNewsWire • 03/03/25
MBX Biosciences Announces Positive Phase 1 Topline Results for MBX 1416 for the Treatment of Post-bariatric HypoglycemiaGlobeNewsWire • 01/07/25
MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric HypoglycemiaGlobeNewsWire • 11/18/24
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual MeetingGlobeNewsWire • 09/30/24
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewsWire • 09/16/24